{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:23:42Z","timestamp":1785551022914,"version":"3.56.0"},"reference-count":27,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T00:00:00Z","timestamp":1484784000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T00:00:00Z","timestamp":1484784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1002\/nau.23210","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T11:38:39Z","timestamp":1484825919000},"page":"1703-1710","source":"Crossref","is-referenced-by-count":23,"title":["Could urinary nerve growth factor be a biomarker for overactive bladder? A meta-analysis"],"prefix":"10.1002","volume":"36","author":[{"given":"Wei","family":"Sheng","sequence":"first","affiliation":[{"name":"University Clinic; Rheinisch Friedrich-Wilhelms University-Clinic of Urology\/Neuro-Urology; Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology; The First People's Hospital of Changde; Changde China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirschner-Hermanns","family":"Ruth","sequence":"additional","affiliation":[{"name":"University Clinic; Rheinisch Friedrich-Wilhelms University-Clinic of Urology\/Neuro-Urology; Bonn Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,1,19]]},"reference":[{"key":"10.1002\/nau.23210-BIB0001|nau23210-cit-0001","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.juro.2012.08.187","article-title":"Urinary neurotrophic factors in healthy individuals and patients with overactive bladder","volume":"189","author":"Antunes-Lopes","year":"2013","journal-title":"J Urol"},{"key":"10.1002\/nau.23210-BIB0002|nau23210-cit-0002","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/nau.22438","article-title":"Neurotrophinsin bladder function: what do we know and where do we go from here","volume":"33","author":"Cruz","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.23210-BIB0003|nau23210-cit-0003","unstructured":"Wells GA Shea B O'Connell D http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"10.1002\/nau.23210-BIB0004|nau23210-cit-0004","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"10.1002\/nau.23210-BIB0005|nau23210-cit-0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/nau.23210-BIB0006|nau23210-cit-0006","first-page":"15","article-title":"Assessing the influence of a single study in the meta-analysis estimate","volume":"8","author":"Tobias","year":"1999","journal-title":"Stata Tech Bull"},{"key":"10.1002\/nau.23210-BIB0007|nau23210-cit-0007","unstructured":"JPT Higgins S Green Cochrane Handbook for Systematic Reviews of Interventions http:\/\/handbook.cochrane.org\/chapter_7\/7_7_3_5_medians and_interquartile_ranges.htm"},{"key":"10.1002\/nau.23210-BIB0008|nau23210-cit-0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1002\/nau.23210-BIB0009|nau23210-cit-0009","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/j.1464-410X.2009.08380.x","article-title":"Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder","volume":"103","author":"Liu","year":"2009","journal-title":"BJU Int"},{"key":"10.1002\/nau.23210-BIB0010|nau23210-cit-0010","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/nau.20938","article-title":"Elevation of serum C-reactive protein in patients with OAB and IC\/BPS implies chronic inflammation in the urinary bladder","volume":"30","author":"Chung","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.23210-BIB0011|nau23210-cit-0011","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3349\/ymj.2015.56.1.204","article-title":"NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome","volume":"56","author":"Kim","year":"2015","journal-title":"Yonsei Med J"},{"key":"10.1002\/nau.23210-BIB0012|nau23210-cit-0012","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/nau.22832","article-title":"Reliability and validity of urinary nerve growth factor measurement in women with lower urinary tract symptoms","volume":"35","author":"Vijaya","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.23210-BIB0013|nau23210-cit-0013","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/nau.20599","article-title":"Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention","volume":"28","author":"Liu","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.23210-BIB0014|nau23210-cit-0014","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/nau.20599","article-title":"Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention","volume":"28","author":"Ciftci","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.23210-BIB0015|nau23210-cit-0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/nau.20599","article-title":"Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention","volume":"28","author":"Liu","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.23210-BIB0016|nau23210-cit-0016","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00192-014-2424-8","article-title":"Urinary nerve growth factor correlates with the severity of urgency and pain","volume":"25","author":"Kim","year":"2014","journal-title":"Int Urogynecol J"},{"key":"10.1002\/nau.23210-BIB0017|nau23210-cit-0017","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/nau.20741","article-title":"Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence","volume":"29","author":"Kuo","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.23210-BIB0018|nau23210-cit-0018","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.juro.2008.01.146","article-title":"Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder","volume":"179","author":"Liu","year":"2008","journal-title":"J Urol"},{"key":"10.1002\/nau.23210-BIB0019|nau23210-cit-0019","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1442-2042.2005.01140.x","article-title":"Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom","volume":"12","author":"Kim","year":"2005","journal-title":"Int J Urol"},{"key":"10.1002\/nau.23210-BIB0020|nau23210-cit-0020","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/nau.21118","article-title":"Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy","volume":"30","author":"Liu","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.23210-BIB0021|nau23210-cit-0021","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1464-410X.2010.09585.x","article-title":"Urinary nerve growth factor in women with overactive bladder syndrome","volume":"107","author":"Liu","year":"2011","journal-title":"BJU Int"},{"key":"10.1002\/nau.23210-BIB0022|nau23210-cit-0022","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22939","article-title":"The use of biomarkers in the diagnosis and treatment of overactive bladder: can we predict the patients who will be resistant to treatment","author":"Alkis","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.23210-BIB0023|nau23210-cit-0023","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23011","article-title":"Urinary neurotrophic peptides in postmenopausal women with and without overactive bladder","author":"Pennycuff","year":"2016","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.23210-BIB0024|nau23210-cit-0024","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11255-013-0540-x","article-title":"Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder","volume":"46","author":"Wang","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1002\/nau.23210-BIB0025|nau23210-cit-0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.juro.2012.08.187","article-title":"Urinary neurotrophic factors in healthy individuals and patients with overactive bladder","volume":"189","author":"Antunes-Lopes","year":"2013","journal-title":"J Urol"},{"key":"10.1002\/nau.23210-BIB0026|nau23210-cit-0026","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/nau.21022","article-title":"Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target","volume":"30","author":"Ochodnicky","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1002\/nau.23210-BIB0027|nau23210-cit-0027","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5213\/inj.2011.15.1.48","article-title":"Urodynamic detrusor overactivity in patients with overactive bladder symptoms","volume":"15","author":"Al-Ghazo","year":"2011","journal-title":"Int Neurourol J"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fnau.23210","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/nau.23210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T17:37:33Z","timestamp":1625333853000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.23210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,19]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1002\/nau.23210","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727222372.793528859","asserted-by":"object"}]},"ISSN":["0733-2467"],"issn-type":[{"value":"0733-2467","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1,19]]}}}